USA flag logo/image

An Official Website of the United States Government

Diverse Neutralizing Human Monoclonal Antibodies to CMV

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
65921
Program Year/Program:
2003 / SBIR
Agency Tracking Number:
AI051760
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
AVANIR PHARMACEUTICALS
AVANIR PHARMACEUTICALS 11388 SORRENTO VALLEY RD, STE 200 SAN DIEGO, CA 92121 0134
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2003
Title: Diverse Neutralizing Human Monoclonal Antibodies to CMV
Agency: HHS
Contract: 1R43AI051760-01A1
Award Amount: $100,000.00
 

Abstract:

DESCRIPTION (provided by applicant): The long-term goal of this proposal (Phase I and II) is to develop a human monoclonal antibody-based preparation for use in treating CMV infections or transmission. Commercial applications for human monoclonal antibodies are extensive. Phase I specific aims are: 1) Screen matching plasma of random buffy coats to identify CMV immune donors, and engraft selected donor cells in SCID mice (hu-PBL-SCID system). 2) Immunize with recombinant gB or gH proteins (neutralizing targets for CMV), and detect specific serum antibodies by ELISA. Optional EBV super-infection may be used. 3) Harvest cells from selected mice, and isolate antigen specific human B/plasma cells by a novel method (antibody rescue technology). Clone heavy and light chain V regions from cells by RT-PCR. 4) Isolate transiently transfected cells producing antigen-specific human monoclonal antibodies. Characterize these for epitope group, affinity, neutralizing capacity, and strain specificity. The main goal of the phase II proposal will be the configuration of at least one combination of human monoclonals for treatment of CMV infection. The phase II SBIR proposal may initially require the leneration of a larger panel of antibodies, based on the success of phase I.

Principal Investigator:

Phillip R. Morrow
8586225257
PMORROW@AVANIR.COM

Business Contact:

David Hansen
8586225215
DHANSEN@AVANIR.COM
Small Business Information at Submission:

AVANIR PHARMACEUTICALS
AVANIR PHARMACEUTICALS 11388 SORRENTO VALLEY RD, STE 200 SAN DIEGO, CA 92121

EIN/Tax ID: 330314804
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No